Teva Announces New Olanzapine LAI (TEV-‘749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adultsfinancialpost.com15h agoRead at financialpost.comEarlier from this sourceMISSION SUCCESS: Rocket Lab Launches 96th Electron Mission7h agoCollective Metals Announces Management Changes11h agoLiberty Gold Files Feasibility Study Technical Report for the Black Pine Project in Idaho, USA12h agoAjax library workers reject two-tier contract: ‘We need a fair deal for everyone’12h agoGreenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States12h agoOttawa’s ‘mega deduction’ tax write-off could boost these TSX stocks, analysts say13h agoNews of the day: The antagonist next door, variable-rate’s moment, how high will interest rates go, workplace investigations, dual-citizen taxes and more14h agoPIMCO Canada Corp. Announces Monthly Distributions for PIMCO Canada Closed End Funds14h agoHow this page changedShareSign in to saveLink